CBC Investment I-Mab Ltd - 29 Jan 2025 SCHEDULE 13D Report for I-MAB Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares) (IMAB)

Filing manager
CBC Investment I-Mab Ltd
Reporting owner
Wei Fu
Security
I-MAB Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares)
Beneficially owned shares
33,571,163 shares
Ownership signal CIK-linked ownership evidence from parsed SEC filings. 2 signals
Large-stake signal

Form

SCHEDULE 13D

Active or control-oriented beneficial ownership filing.

Ownership

18%

Beneficial ownership of this reported class.

Shares

33,571,163 shares

Shares beneficially owned as disclosed.

Event date

29 Jan 2025

Date tied to the ownership event or amendment.

Accepted by SEC

05 Feb 2025

EDGAR acceptance date.

How to read this large-stake filing
  • Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
  • Compare this filing with the holder history and issuer page before treating the percentage as a current position.
  • Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
Class ownership
18%
Subject security Names, identifiers, and filing context for this profile. 2 source fields
Symbol
IMAB
Shares outstanding
187,548,397 shares
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
SCHEDULE 13D
Accepted by SEC
05 Feb 2025, 20:09:55 UTC
Event date
29 Jan 2025
Next SEC filing
07 Aug 2025
Source filing
View source filing

Key filing fact

CBC Investment I-Mab Ltd disclosed 18% ownership in I-MAB Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares) (IMAB) on 29 Jan 2025.

Key facts

  • CBC Investment I-Mab Ltd filed SCHEDULE 13D for I-MAB Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares) (IMAB).
  • Disclosed ownership: 18%.
  • Date of event: 29 Jan 2025.

Change

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 05 Feb 2025, 20:09.

Research use

  • This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
  • Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.

Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

View source filing

Reporting persons

Disclosed reporting parties (13)

Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.

Name Ownership Shares owned Sole voting power Shared voting power Signature Title CIK
CBC Investment I-Mab Limited 6.3% 11,784,164 0 11,784,164 /s/ Wei Fu Wei Fu - Director 0001845246
IBC Investment Seven Limited 1.9% 3,641,554 0 3,641,554 /s/ Wei Fu Wei Fu - Director
CBC SPVII LIMITED 3% 5,574,560 0 5,574,560 /s/ Wei Fu Wei Fu - Director
C-Bridge II Investment Ten Limited 1.3% 2,369,546 0 2,369,546 /s/ Wei Fu Wei Fu - Director
Everest Medicines Limited 3.2% 6,078,571 0 6,078,571 /s/ Xiaofan Zhang Xiaofan Zhang - Director
Nova Aqua Limited 2.2% 4,122,768 4,122,768 0 /s/ Wei Fu Wei Fu - Authorized Signatory
C-Bridge Healthcare Fund II, L.P. 7.6% 14,153,710 0 14,153,710 /s/ Wei Fu Wei Fu - Authorized Representative
C-Bridge Healthcare Fund GP II, L.P. 7.6% 14,153,710 0 14,153,710 /s/ Wei Fu Wei Fu - Authorized Representative
C-Bridge Capital GP, Ltd. 12% 23,369,824 0 23,369,824 /s/ Wei Fu Wei Fu - Director
I-Bridge Healthcare Fund, L.P. 4.9% 9,216,114 0 9,216,114 /s/ Wei Fu Wei Fu - Authorized Representative
I-Bridge Healthcare GP, L.P. 4.9% 9,216,114 0 9,216,114 /s/ Wei Fu Wei Fu - Authorized Representative
I-Bridge Capital GP, Ltd. 4.9% 9,216,114 0 9,216,114 /s/ Wei Fu Wei Fu - Director
Wei Fu 18% 33,571,163 0 33,571,163 /s/ Wei Fu Wei Fu
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .